David Nielsen

Dr. David Nielsen

orcid

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2005 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MKMary Jeanne Kreek
Mary Jeanne Kreek
DNDavid Nielsen
David Nielsen
EBEduardo R Butelman
Eduardo R Butelman
KLK Steven LaForge
K Steven LaForge

1 March 2005 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
MKMary Jeanne Kreek
Mary Jeanne Kreek
GBGavin Bart
Gavin Bart
CLCharles Lilly
Charles Lilly
KLK. Steven Laforge
K. Steven Laforge
DNDavid Nielsen
David Nielsen
Opiate and cocaine addictions are major social and medical problems that impose a significant burden on society. Despite the size and scope of these problems, there are few effective treatments for these addictions. Methadone maintenance is an effective and most widely used treatment for opiate addiction, allowing normalization of many physiological abnormalities caused by chronic use of short-acting opiates. There are no pharmacological treatments for cocaine addiction. Epidemiological, linkage, and association studies have demonstrated a significant contribution of genetic factors to the addictive diseases. This article reviews the molecular genetics and pharmacogenetics of opiate and cocaine addictions, focusing primarily on genes of the opioid and monoaminergic systems that have been associated with or have evidence for linkage to opiate or cocaine addiction. This evidence has been marshaled either through identification of variant alleles that lead to functional alterations of gene products, altered gene expression, or findings of linkage or association studies. Studies of polymorphisms in the μ opioid receptor gene, which encodes the receptor target of some endogenous opioids, heroin, morphine, and synthetic opioids, have contributed substantially to knowledge of genetic influences on opiate and cocaine addiction. Other genes of the endogenous opioid and monoaminergic systems, particularly genes encoding dopamine β-hydroxylase, and the dopamine, serotonin, and norepinephrine transporters have also been implicated. Variants in genes encoding proteins involved in metabolism or biotransformation of drugs of abuse and also of treatment agents are reviewed.

1 January 1994 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
DNDavid Nielsen
David Nielsen
DGDavid Goldman
David Goldman
MVMatti Virkkunen
Matti Virkkunen
RTRiitta Tokola
Riitta Tokola
RRRobert Rawlings
Robert Rawlings
MLMarkku Linnoila
Markku Linnoila
From JAMA Psychiatry — Suicidality and 5-Hydroxyindoleacetic Acid Concentration Associated With a Tryptophan Hydroxylase Polymorphism

1 July 1998 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
DNDavid Nielsen
David Nielsen
MVMatti Virkkunen
Matti Virkkunen
JLJaakko Lappalainen
Jaakko Lappalainen
MEMonica Eggert
Monica Eggert
GBGerald L. Brown
Gerald L. Brown
MLMarkku Linnoila
Markku Linnoila
FAMILY, ADOPTION, and twin studies have demonstrated heritability and familial transmission of suicidality1,2 and alcoholism.3-5 In fact, suicidality and alcoholism may share common genetic vulnerability variables. A major risk factor for suicidality is alcoholism. Compared with the general population, alcoholism increases the risk of suicide 60- to 120-fold when comorbid with a mental disorder.6 Furthermore, alcoholism is diagnosed ante mortem in 25% of suicide victims.7

30 September 2008 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
OLOrna Levran
Orna Levran
DLD. Londono
D. Londono
KOK. O’hara
K. O’hara
DNDavid Nielsen
David Nielsen
EPE. Peles
E. Peles
MKM. J. Kreek
M. J. Kreek
Heroin addiction is a chronic complex disease with a substantial genetic contribution. This study was designed to identify genetic variants that are associated with susceptibility to develop heroin addiction by analyzing 1350 variants in 130 candidate genes. All subjects had Caucasian ancestry. The sample consisted of 412 former severe heroin addicts in methadone treatment, and 184 healthy controls with no history of drug abuse. Nine variants, in six genes, showed the lowest nominalPvalues in the association tests (P < 0.01). These variants were in noncoding regions of the genes encoding the mu (OPRM1; rs510769 and rs3778151), kappa (OPRK1; rs6473797) and delta (OPRD1; rs2236861, rs2236857 and rs3766951) opioid receptors; the neuropeptide galanin (GAL; rs694066); the serotonin receptor subtype 3B (HTR3B; rs3758987) and the casein kinase 1 isoform epsilon (CSNK1E; rs1534891). Several haplotypes and multilocus genotype patterns showed nominally significant associations (e.g.OPRM1;P = 0.0006 andCSNK1E;P = 0.0007). Analysis of a combined effect ofOPRM1andOPRD1showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). None of these associations remained significant after adjustment for multiple testing. This study suggests the involvement of several genes and variants in heroin addiction, which is worthy of future study.

3 June 2007 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
TKThomas Kroslak
Thomas Kroslak
KLK. Steven LaForge
K. Steven LaForge
RGRobert J. Gianotti
Robert J. Gianotti
AHAnn Ho
Ann Ho
DNDavid Nielsen
David Nielsen
MKMary Jeanne Kreek
Mary Jeanne Kreek
The most common single nucleotide polymorphism in the coding region of the human mu opioid receptor gene is the A118G variant, an adenine to guanine transition at nucleotide position 118 of the coding sequence of the gene. This polymorphism codes for an asparagine to aspartic acid substitution at amino acid 40 in the amino‐terminus, thereby removing a potential extracellular glycosylation site. Usingin vitrocellular expression assays, this variant has been reported to change binding of the endogenous agonist beta‐endorphin and signaling of the receptor following binding of beta‐endorphin. Three clinical studies report that A118G genotype affects opioid antagonist‐mediated increases in cortisol levels. These studies demonstrate a functional role of this variant in responses to endogenous and exogenous opioids. To further characterize function, we expressed the prototype and variant receptors in two types of cells (human 293 embryonic kidney cells and Syrian hamster adenovirus‐12‐induced tumor cells). Stable expression of variant and prototype receptors was characterized by differences in levels of cell surface binding capacity (Bmax), forskolin‐induced cAMP accumulation, as well as agonist‐induced accumulation of cAMP (EC50) for several agonists, but not for beta‐endorphin. In contrast, transiently expressed variant receptors showed only a minor difference in cell surface binding capacity compared to the prototype, and no differences in cAMP EC50values.